Communiqués Ovid Therapeutics Inc.

Actions

OVID

US6904691010

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/07/2026			Varia. 5j.	Varia. 1 janv.
2,520 ^USD	-3,08%		-6,32%	+54,60%

08/07	Ovid Therapeutics nomme Kevin Norrett au poste de Chief Business Officer et promeut ses directeurs financier et de la stratégie	MT
08/07	Ovid Therapeutics Inc. annonce des changements au sein de sa direction, effectifs au 6 juillet 2026	CI

Communiqués

08/07	Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development	GL
04/06	Ovid Therapeutics to Participate in Upcoming Investor Conferences	GL
03/06	Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors	GL
03/06	Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors	AQ
12/05	Ovid Therapeutics : May 2026 Corporate Presentation	PU
12/05	Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results	GL
14/04	Ovid Therapeutics : KCC2 Deep Dive Day	PU
08/04	Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14	GL
08/04	Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14	AQ
18/03	Ovid Therapeutics : Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results	PU
18/03	Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results	GL
18/03	Ovid Therapeutics Announces Pricing of $60 Million Private Placement	GL
25/02	Ovid Therapeutics to Participate in Upcoming Investor Conferences	GL
13/01	Ovid Therapeutics : January 2026 Corporate Presentation	PU
19/12	Ovid Therapeutics Reports Phase 1 results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2, OV350 Intravenous	AQ
18/12	Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)	GL
02/12	Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer	GL
14/11	Ovid Therapeutics : November 2025 Corporate Presentation	PU
12/11	Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results	GL
12/11	Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results	AQ
03/10/25	Ovid Therapeutics : OV329 Topline Data Presentation	PU
03/10/25	Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds	GL
03/10/25	Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile	GL
13/08/25	Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results	GL
23/07/25	Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference	GL